ライフサイエンスコーパス: CYP27B1

1 etabolites among pregnant women [including a CYP27B1-associated increase in 1,25(OH)2D3] and the evid

2 p, CaR expression increased 39% (P=0.01) and CYP27B1 expression increased 159% (P=0.06).

3 sion of cytochrome P450 enzyme (CYP)27A1 and CYP27B1, however, having only slight effect on CYP24.

4 In HCEC, 24,25(OH)2D3 increased CYP24A1 and CYP27B1 mRNA and protein expression, and stimulated cell

5 n the other hand, increased both CYP24A1 and CYP27B1 protein expression in WT and VDR KO cells, and s

6 ells (KO), 1,25(OH)2D3 increased CYP24A1 and CYP27B1 protein expression.

7 ndrial cytochrome P450s (CYP24A, CYP27A, and CYP27B1) has been described that catalyze the formation

8 The polymorphisms of GC, CYP2R1 and CYP27B1 were not associated with treatment outcome even

9 found for SNPs in genes GC, VDR, CYP2R1, and CYP27B1.

10 rted association between type 1 diabetes and CYP27B1 (P = 1.4 x 10(-4)), we obtained consistent evide

11 the vitamin D-binding protein gene (Gc) and CYP27B1 and CYP24A1, which code for enzymes that, respec

12 DR downstream genes (VDR, CYP24A1, TRPV6 and CYP27B1), and inhibit the production of inflammatory mar

13 ntervention were modified by SNPs in VDR and CYP27B1.

14 zyme cytochrome P450scc (CYP11A1) as well as CYP27B1 (1alpha-hydroxylase).

15 e on the kinetics of 1alpha-hydroxylation by CYP27B1 were determined.

16 /cell type specificity and being modified by CYP27B1 activity.

17 ired functional mast cell-VDRs and mast cell-CYP27B1.

18 on variants in the 12q14.1 region containing CYP27B1 in multiple sclerosis (MS).

19 Nine polymorphisms in VDR, CYP24A, CYP27B1, GC, and RXRA were analyzed as effect modifiers

20 Sequencing analysis of the VDR, CYP24A1, CYP27B1 and CYP2R1 detected twelve nucleotide changes in

21 iated steps of vitamin D activation (CYP2R1, CYP27B1) and inactivation (CYP24A1, CYP3A4) and the newe

22 ve vitamin D-related genes (CYP27A1, CYP2R1, CYP27B1, GC and VDR) were genotyped in 1442 Chinese chil

23 lcium pathway genes (VDR, GC, DHCR7, CYP2R1, CYP27B1, CYP24A1, and CASR) modify the effects of vitami

24 D receptor (VDR), and the P450 cytochromes, CYP27B1 and CYP24A1; however, they have yet to be invest

25 sed CYP24A1 protein expression and decreased CYP27B1 expression.

26 5-hydroxyvitamin D-1alpha-hydroxylase (i.e., CYP27B1), leading to enhanced bioconversion of 25-hydrox

27 tion, and on the vitamin D activating enzyme CYP27B1 (produces 1,25(OH)2D3) and inactivating enzyme C

28 The mitochondrial enzyme CYP27B1 catalyzes 1 alpha-hydroxylation in the kidney bu

29 amin D (1,25D) by the cytochrome P450 enzyme CYP27B1 in kidney and other tissues.

30 in the kidney via the cytochrome P450 enzyme CYP27B1.

31 Colorectal carcinoma cells express CYP27B1 and CYP24A1 that locally regulate 1,25D with pot

32 olon cancer cells that expressed one of five CYP27B1 single-nucleotide polymorphisms (SNP) or four CY

33 red with the wild-type control, four of five CYP27B1 SNPs reduced enzymatic activity, whereas one (V1

34 ence of association with type 1 diabetes for CYP27B1 -1260 and +2838 polymorphisms, which are in perf

35 ts provide evidence against a major role for CYP27B1 mutations in MS.

36 We studied four CYP27B1 variants, including common polymorphisms -1260C>

37 has recently been reported that heterozygous CYP27B1 mutations are associated with increased MS susce

38 zyme, 25-hydroxyvitamin D 1alpha-hydroxylase CYP27B1.

39 g 25-hydroxyvitamin D(3) 1alpha-hydroxylase (CYP27B1(-/-)), and having no circulating 1,25(OH)(2)D(3)

40 cell-25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and mast cell-VDR activity.

41 amin D-activating enzyme 1alpha-hydroxylase (CYP27B1) and vitamin D receptor (VDR) support anti-infla

42 of CYP2R1 with vitamin D 1alpha-hydroxylase (CYP27B1) elicited additive activation of vitamin D3, whe

43 covery of the extrarenal 1alpha-hydroxylase (CYP27B1) in various vitamin D target tissues around the

44 by the enzyme 25(OH)D(3)-1alpha-hydroxylase (CYP27B1) into active 1,25(OH)(2)D(3).

45 of 25-hydroxyvitamin D3-1alpha-hydroxylase (CYP27B1) mRNA was markedly increased in renal proximal c

46 yme 25-hydroxyvitamin D3-1alpha-hydroxylase (CYP27B1), which can be expressed by activated immune cel

47 -regulated expression of 1alpha-hydroxylase (CYP27B1, 1alphaOHase), the enzyme that converts 25-hydro

48 and 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1: rs4646536) (adjusted hazard ratio >/= 1.47; P f

49 n D3 [1,25(OH)2D3]; and 1alpha-hydroxylase [(CYP27B1) with 3-epi-25(OH)D3 and 1,25(OH)2D3].

50 on sequencing to identify a rare mutation in CYP27B1 in a MS family is also discussed.

51 The demonstration that rare variants in CYP27B1, which encodes the enzyme that converts vitamin

52 1,25(OH)2D3 increased CYP27B1 mRNA levels in HCEC, but had no effect on CYP27B

53 ke receptor 2/1 heterodimer (TLR2/1)-induced CYP27B1 and IL1B expression as well as indirectly upregu

54 Blocking the vitamin D receptor, inhibiting CYP27B1, or limiting 25D3 availability prevented TGF-bet

55 Mechanistically, CYP27B1 is induced in DCs upon maturation with LPS or up

56 The common C allele of CYP27B1 -1260 was associated with an increased disease r

57 The wide distribution of CYP27B1, the enzyme required to convert circulating 25OH

58 Given the high basal expression of CYP27B1 and VDR in trophoblastic cells from the placenta

59 CS exposure decreased expression of CYP27B1 and was especially pronounced in patients with C

60 ntly, CT greatly increased the expression of CYP27B1 mRNA in the kidney of normocalcemic sham-TPTX ra

61 CT also increased the expression of CYP27B1 mRNA in the kidney of normocalcemic TPTX rats.

62 tion of PTH did not induce the expression of CYP27B1 mRNA in the kidney of vitamin D-replete sham-TPT

63 Their kinetics of CYP27B1 metabolism were investigated during the producti

64 was explained by findings that the levels of CYP27B1, which converts 25OH vitamin D3 (25D3) to active

65 lecular mechanisms involved in regulation of CYP27B1 have remained undefined.

66 B1 mRNA levels in HCEC, but had no effect on CYP27B1 protein levels.

67 ast cells that did or did not express VDR or CYP27B1.

68 Although the cytochrome P450 CYP27B1 plays a critical role in vitamin D biology, the

69 Rare CYP27B1 mutations cause autosomal recessive vitamin D-de

70 major regulator for the expression of renal CYP27B1 is parathyroid hormone (PTH).

71 PTH increased the expression of renal CYP27B1 mRNA only in vitamin D-deficient hypocalcemic TP

72 d calcitonin (CT) on the expression of renal CYP27B1 mRNA was investigated in normocalcemic sham-oper

73 c state, the mechanism to regulate the renal CYP27B1 gene could be different, since plasma levels of

74 rs2282679), CYP2R1 (rs2060793, rs12794714), CYP27B1 (rs10877012), and DHCR7 (rs12785878).

75 By sequencing CYP27B1 in 134 multiplex families and genotyping the mos

76 aim was to study the association between the CYP27B1 and CYP24A1 gene polymorphisms and type 1 diabet

77 he enzyme 1 alpha-hydroxylase encoded by the CYP27B1 gene and is inactivated by 24-hydroxylase encode

78 sclerosis and the rare mutant alleles of the CYP27B1 gene responsible for autosomal recessive vitamin

79 ase (1alpha-hydroxylase), the product of the CYP27B1 gene.

80 n convert 25OHD3 to 1alpha,25(OH)2D3 through CYP27B1 activity and that both of these vitamin D3 metab

81 CYP24A1, having selectivity with respect to CYP27B1 comparable with or greater than that of the stan

82 against colorectal neoplasms, and CaR, VDR, CYP27B1, and CYP24A1 as modifiable, preneoplastic risk b

83 CaR, VDR, CYP27B1, and CYP24A1 expression and distribution in biop

84 elop chemically induced skin tumors, whereas CYP27B1(-/-) and wild-type mice do not, indicating that

85 CD14, or TLR2 in human keratinocytes, while CYP27B1-deficient mice failed to increase CD14 expressio